The Impact of PCSK9 Inhibitors on Development of Retinal Vascular Occlusions
Listen to this summary
This study investigates the relationship between the use of PCSK9 inhibitors (PCSK9i) and the risk of developing retinal vascular occlusions in patients with hyperlipidemia. The authors found that patients prescribed PCSK9i had a significantly lower risk of retinal artery and vein occlusions over a seven-year period compared to those on other lipid-lowering medications, suggesting that PCSK9i may offer protective microvascular effects.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from American journal of ophthalmology
View all →Jun 24, 2026 · American journal of ophthalmology
Corneal Epithelial Alterations Associated With CDK4/6 Inhibitor Therapy in Hormone Receptor-Positive Breast Cancer
Jun 23, 2026 · American journal of ophthalmology
Dopamine-Enhancing Therapies and Risk of Neovascular AMD Conversion: A Target Trial Emulation
Jun 23, 2026 · American journal of ophthalmology
Associations Between Routine Vaccinations and the Risk of New-Onset Idiopathic Uveitis
Jun 22, 2026 · American journal of ophthalmology
Association between statin use and dry eye disease: A systematic review and meta-analysis
Jun 22, 2026 · American journal of ophthalmology
Therapeutic response to anti-VEGF retreatment among eyes with stabilized vision after being lost to follow-up in diabetic macular edema: A nationwide, registry-based cohort study
Jun 21, 2026 · American journal of ophthalmology
Zeb1 mediates injury-induced mesenchymal transition in the mouse corneal endothelium in vivo
More in Ophthalmology
View all →Jun 24, 2026 · Lancet (London, England)
Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, randomised controlled trial
Jun 24, 2026 · The New England journal of medicine
A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis
Jun 24, 2026 · The New England journal of medicine
Prevention and Treatment of Peanut Allergy
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
Jun 24, 2026 · The New England journal of medicine
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
Jun 23, 2026 · Lancet (London, England)
Combined bladder-kidney transplantation: first-in-human feasibility trial
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
